微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 17.93% | -22.75% | -8.63% | 136/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 19.63% | -48.89% | -4.23% | 138/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 20.5% | -51.46% | -7.9% | 139/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 22.25% | -51.28% | -4.15% | 139/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 23.22% | -49.92% | -39.55% | 133/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 38.4% | -15.1% | -9.04% | 110/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 42.22% | -4.15% | -7.57% | 100/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 45.68% | 0.78% | -1.46% | 91/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 46.36% | 7.35% | 2.48% | 89/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 45.24% | 12.28% | 2.68% | 92/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 44.05% | 2% | -2.81% | 91/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 45.32% | 8.46% | 4.96% | 88/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 43.18% | 2% | 7.18% | 91/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 40.29% | -14.76% | -3.59% | 104/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 41.79% | -19.78% | -11.59% | 95/159 | 47.45% | 艾力斯 | 99.41% | 行业排名> |
| 2020-12-31 | 47.27% | -5.17% | -9.27% | 86/159 | -144.37% | 艾力斯 | 98.7% | 行业排名> |
| 2020-06-30 | 52.09% | 36.24% | 4.52% | 69/159 | 54.32% | 艾力斯 | 99.4% | 行业排名> |
| 2019-12-31 | 49.84% | 17.71% | 17.71% | 79/159 | -1213.38% | 首药控股 | 99.94% | 行业排名> |
| 2018-12-31 | 42.34% | 7.92% | 10.74% | 88/159 | -205.91% | 泽璟制药 | 99.96% | 行业排名> |
| 2018-06-30 | 38.24% | -7.22% | -2.55% | 79/159 | 53.68% | 微芯生物 | 95.14% | 行业排名> |
| 2017-12-31 | 39.24% | 2% | -4.79% | 80/159 | 52.58% | 多瑞医药 | 95.59% | 行业排名> |
| 2017-06-30 | 41.21% | 2% | 2% | 60/159 | 48.02% | 微芯生物 | 95.81% | 行业排名> |